Introduction
Vascular injury is an early manifestation leading to end-organ damage in hypertension. 1 Angiotensin (Ang) II, one of the final mediators of the renin-angiotensin-aldosterone system, plays an important role in the development of hypertension and vascular injury. 2 Ang II participates in the pathophysiology of hypertension by increasing blood pressure (BP) through vasoconstriction and its renal actions and by causing small artery injury. The latter is characterized by endothelial dysfunction and vascular remodelling, oxidative stress and inflammation. 1, 3, 4 However, the mechanisms whereby Ang II induces vascular injury are complex, and have not been definitively clarified in their entirety. Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of hypertension and its complications. [5] [6] [7] [8] MMPs are members of a superfamily of zinc-dependent endopeptidases that are involved in extracellular matrix (ECM) remodelling through collagen, elastin, and fibronectin degradation. 5, [8] [9] [10] MMPs also play a role in vascular remodelling by shedding growth factors such as heparin-binding epidermal growth factor (HB-EGF) 11 and ECM-bound latent transforming growth factor (TGF) b. 12 In addition, MMPs could modulate vascular tone by cleaving big-endothelin-1 and other vasoactive peptides. 13 MMPs are expressed in the vascular system in vascular smooth muscle cells (VSMCs) and endothelial cells (ECs). 5 A systematic review and metaanalysis showed that plasma levels of MMP2, a gelatinase, are predictive of diastolic left ventricular dysfunction in hypertensive patients. 14 
MMP2
expression is increased in cardiovascular tissues in hypertensive models such as Ang II-infused mice, 15, 16 two-kidney, one-clip (2K-1C) rats, 17, 18 and chronic nitric oxide (NO) synthase inhibition with N x -nitro-L-arginine methyl ester (L-NAME) in rats. 18 Transverse aortic constriction (TAC)-induced pressure overload also causes an elevation in cardiac MMP2 expression. 19 Interestingly, inhibition of MMPs with the nonselective MMP inhibitor doxycycline reduced the rise in BP and aortic endothelial dysfunction, hypertrophic remodelling and fibrosis in 2K-1C rats, 17 Doxycycline also blunted L-NAME-induced aortic hypertrophic remodelling but not mesenteric artery eutrophic remodelling in rats. 18 Mmp2 targeted gene deletion prevented pressure overload-induced cardiac hypertrophy, dysfunction and fibrosis. 19 A MMP2 selective inhibitor or RNA interference targeting the Mmp2 gene prevented Ang II-induced hypertension but not cardiac hypertrophy and fibrosis. 15 In another study, Mmp2 knockout did not affect the development of hypertension but resulted in greater cardiac hypertrophy and fibrosis in Ang II-treated mice. 20 However, whether Mmp2 knockout prevents the development of vascular injury in hypertension has never been tested. We hypothesized that Mmp2-targeted gene deletion could prevent Ang II-induced vascular injury. In order to test this hypothesis, we first determined whether Ang II-induced hypertension and vascular injury were blunted in Mmp2 -/-mice. Then we examined if Ang II signalling was reduced by Mmp2 knockout in VSMCs in vitro. Finally, we determined the contribution of MMP2 expressed in vascular and immune cells to Ang II detrimental effects using bone marrow (BM) cell transplantation from wild-type (WT) into irradiated Mmp2 -/-mice and vice versa.
Methods
An expanded Methods section is available in the Supplementary material online. Medical Research) were anaesthetized with 3% isoflurane mixed with O 2 at 1 L/min. The depth of anaesthesia was confirmed by the rear foot squeezing. The non-steroidal anti-inflammatory drug carprofen (20 mg/ kg) was administered SC to minimize the post-operation pain, and then mice were surgically implanted SC with ALZET osmotic mini pumps (Model 1002, Durect Corporation, Cupertino, CA, USA) infusing Ang II (1000 ng/kg/min) for 14 days, as previously described. 22 Control mice underwent sham surgery. A subset of the mice were anaesthetized with isoflurane and surgically instrumented with PA-C10 telemetry transmitters 7-10 days before Ang II treatment and BP was determined from two days before Ang II mini pump or sham surgery until the mice were sacrificed, as previously described. 22 At the end of the protocol, mice were weighed and then anaesthetized with isoflurane. The mesenteric arterial vascular bed was dissected, and tissues and tibia harvested in icecold phosphate buffered saline. Tissues were weighed and tibia length measured. The spleen was used for monocyte and T cell profiling. Second-order branches of mesenteric arteries (MA) were used for assessment of endothelial function and vessel mechanics by pressurized myography. 23 Portions of aorta were embedded in Clear Frozen Section
Experimental design
Compound (VWR International, Edmonton, AL, Canada) for determination of reactive oxygen species (ROS) generation with the ROS-sensitive fluorescent dye dihydroethidium, expression of fibronectin, monocyte chemotactic protein-1 (MCP-1) and vascular cell adhesion molecule 1 (VCAM-1) or evaluation of tissue infiltration of monocyte/macrophages and T cells by immunofluorescence, or fixed with 4% paraformaldehyde and embedded in paraffin for quantification of collagen content with Sirius red staining. 24 The remaining tissues were frozen in liquid nitrogen and stored at -80 C until used.
In order to examine the role of MMP2 in Ang II signalling in VSMCs, another set of 8-9-week-old male WT and Mmp2 -/-mice were used to isolate the VSMCs from MA and study Ang II-induced epidermal growth factor receptor (EGFR) signalling. 
-/-) mice as previously described. 25 Four weeks after transplantation, mice were instrumented or not with PA-C10 telemetry transmitters for BP determination, and 7-10 days later BP was determined for two consecutive days before and during the 14-day period of treatment with or without Ang II and studied as above. In addition, blood was collected by cardiac puncture on EDTA. One hundred microlitre of blood was used for confirmation of BM reconstitution and the remaining blood was used for determination of plasma MMP2 and pro-MMP9. BP was also determined in an additional group of BM-transplanted mice infused with L-norepinephrine (4.17 mg/kg/min) using ALZET osmotic pumps for 14 days as previously described. 26 
Data analysis
Results are presented as means ± SEM. Data were compared with twoway analysis of variance (ANOVA) or two-way ANOVA for repeated measures, with all ANOVA tests followed by a Student-Newman-Keuls post hoc test, or with an unpaired t-test, as appropriate. P < 0.05 was considered statistically significant.
Results

BP, body and organ weights
Ang II infusion for 2 weeks caused a similar elevation in systolic BP in WT and Mmp2 -/-mice ( Figure 1A) . Body weight, and heart, lung and kidney weight/tibia length were similar, whereas liver and spleen weight/tibia length were, respectively, smaller and greater in Mmp2 -/-compared with WT mice ( Figure S1 ). Moreover, contractile responses to norepinephrine were unaffected by Ang II (see Supplementary material online, Figure S1A ). Ang II caused impairment of the vasodilatory response to acetylcholine, as indicated by a 50% decrease in the maximal response, in WT but not in Mmp2 -/-mice ( Figure 1B) . NO was the major mediator of the vasodilator response, since acetylcholine-induced relaxation was abrogated in all groups in the presence of the NO synthase inhibitor L-NAME (see Supplementary material online, Figure 1B) . The impaired endothelial vasodilatory response was not due to a VSMC defect since endothelium-independent relaxation responses to the NO donor sodium nitroprusside were similar in all groups (see Supplementary material online, Figure 1C ). In WT mice, Ang II also increased small artery stiffness as indicated by a leftward shift in the stress/strain curve ( Figure  1C) , and caused hypertrophic remodelling demonstrated by a > _1. 4 -fold increase in the media/lumen and cross-sectional area of mesenteric resistance arteries ( Figure 1D and E). Mmp2 deletion prevented Ang II-induced endothelium-dependent relaxation response dysfunction, increase in small artery stiffness and hypertrophic remodelling.
MMP2 is required for Ang II-induced vascular ROS generation and ECM remodelling
Ang II increased ROS generation 10-fold in the aortic media and six-fold in the adventitia and PVAT in WT mice (Figure 2A and D). ROS generation was reduced in Mmp2 -/-mice. Ang II-treated WT mice presented a 1.5-fold increase in the expression of aortic media fibronectin ( Figure 2B and E) and a 1.7-fold increase in adventitial collagen fraction ( Figure 2C and F) compared with untreated WT mice, changes not found in Mmp2 -/-mice. -/-þAng II = 8 and other groups = 9. Data were analyzed using two-way ANOVA followed by a StudentNewman-Keuls post hoc test. *P < 0.05 vs. their respective WT or Mmp2 -/-controls. 
MMP2 is required for Ang II-induced vascular inflammation and immune response
Ang II increased aortic VCAM-1 and MCP-1 expression four-and sevenfold, respectively, in WT mice, increases that were reduced in Mmp2 -/-mice ( Figure 3A , B and E, F). Ang II caused an elevation in monocyte/macrophage (15-fold) and CD3 þ T cell (four-fold) infiltration in PVAT of WT mice, effect that was markedly reduced in Mmp2 -/-mice ( Figure 3C , D and G, H).
MMP2 is required for activation of immune cells at a systemic level. This was demonstrated by the finding that Ang II caused a 50% decrease in the fraction of CD11b þ monocytes and a two-fold increase in activated Ly-6C hi monocytes in the spleen of WT mice, but not in Mmp2 -/-mice ( Figure 4A and B). It should be noted that the fraction of CD11b þ monocytes was lower in Mmp2 -/-than in WT mice and not affected by 
MMP2 is required for Ang II-EGFRdependent signalling in VSMCs
The function of MMPs is not limited to turnover and degradation of ECM, but also involves shedding of HB-EGF with subsequent activation of EGFR and downstream mitogen-activated protein kinases (MAPKs), which could be involved in Ang II-induced vascular injury. 27 Since MMP2 is highly expressed in VSMCs, we investigated whether Mmp2 deficiency affects Ang II signalling in VSMCs isolated from MA in order to demonstrate the Figure S4A and B). Ang II infusion caused a 3.6-fold elevation in plasma MMP2 in WT ! WT mice.
Mmp2
-/-! WT mice presented 2.3-fold more plasma MMP2 than WT ! WT mice, which was not further altered by Ang II infusion. In order to determine whether lack of MMP2 could be compensated by another MMP, plasma pro-MMP9 was measured. Plasma pro-MMP9 levels were similar in WT ! WT, Mmp2 -/-! WT and WT ! Mmp2 online, Figure S6B and F).
In order to determine whether the alteration in Ang II-induced BP rise in absence of vascular or immune MMP2 was selective to this model, an alternative hypertensive agent was tested. Norepinephrine infusion caused similar SBP rise in all groups (see Supplementary material online, Figure S7 ).
Discussion
The present study showed that Mmp2 deletion prevents Ang II-induced endothelial dysfunction, vascular remodelling, oxidative stress, and inflammation in mice. These vascular protective effects could be mediated at least in part through the inhibition of the role that MMP2 plays via shedding of HB-EGF 11 leading to EGFR/ERK1/2 signalling in VSMCs.
Ang II increased Mmp2 expression in aorta/PVAT infiltrating immune cells. As well, BM cell transplantation experiments revealed that Mmp2 deficiency in immune cells reduced BP rise, and lack of Mmp2 in both vascular and immune cells blunted endothelial dysfunction in Ang II infused mice. In this study, endothelial dysfunction, vascular stiffness and remodelling of small MA, oxidative stress and inflammation caused by Ang II were blunted by Mmp2 deletion, whereas BP elevation was not. This is the first study that demonstrates a role of MMP2 in the development of vascular injury independent of BP elevation. The role of MMPs in hypertension has been examined previously using doxycycline, a broad-spectrum MMP inhibitor. Bouvet et al. showed that doxycycline reduced BP elevation and aortic remodelling but not mesenteric artery remodelling in rats subjected to chronic NO synthase inhibition with L-NAME. 18 In 2K-1C hypertension, Castro et al. observed that doxycycline reduced BP and prevented development of aortic endothelial dysfunction and MMP2 mediates vascular damage in hypertension remodelling. 17 The blunting of BP elevation in the above studies could be due to inhibition of multiple MMPs and also to off-target effects of the non-selective MMP inhibitors. Odenbach et al. showed that specific pharmacologic inhibition of MMP2 using the lipid analogue MMP2 inhibitor I, and RNA interference to knock down Mmp2, prevented Ang IIinduced hypertension but not cardiac hypertrophy and fibrosis. 15 More recently, the same group showed that the extent of BP elevation was unaffected but cardiac hypertrophy and pericoronary artery fibrosis were exaggerated in Ang II-treated Mmp2 -/-compared with WT mice. 20 This latter study is in agreement with our current study with respect to BP. However, in our study cardiac hypertrophy was unaffected by absence of MMP2. There are similarities between these results and our previous findings showing that Ang II-induced BP rise and endothelial dysfunction were reduced or blunted in osteopetrotic mice that have a mutation in the colony-stimulating factor gene (Csf1) and an associated decrease in functional monocyte/macrophages, 40 as well as in mice adoptively transferred with T regulatory cells, 22 in which effector T cells and innate immune cells such as dendritic cells, monocytes, and macrophages are suppressed. 3, 4 In this study, Mmp2 deficiency in immune cells prevented Ang II-induced BP rise and endothelial dysfunction. MMP2 could play a role in innate or adaptive immune responses in the pathophysiology of hypertension and vascular injury. This could be mediated through a local MMP2 action, since immune cells contribute very little to circulating MMP2. It has been shown that interaction of monocytes with matrix leads to up-regulation of several MMPs including MMP2. 28 Interestingly, we found that Ang II enhanced MMP2 expression in infiltrating immune cells. MMP2 could contribute to immune cell activation via cytokines such as interleukin-1b. 9 We also observed that the lack of Mmp2 in vascular tissue did not affect Ang II-induced BP rise but blunted endothelial dysfunction. It is unclear why the lack of vascular MMP2 did not impede Ang II pressor responses. However, vascular MMP2 might be important for Ang II-induced vascular injury. Expression of MMP2 in vascular cells could play a role in the attraction and recruitment of monocytes and T cells, as has been suggested in atherosclerosis. 28 This could occur via Ang II-dependent MMP2-mediated EGFR signalling by vascular cells or infiltrating monocyte/macrophages expressing AGTR1, MMP2, and EGFR. 22, 41 This could also rely on MMP2 secretion by vascular or immune cells causing degradation of ECM or activation of nearby immune cells.
Limitations
The present study has focused on determining the role of MMP2 family that includes 24 members. 9 MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs) that inhibit their activity by binding to their catalytic site. There are four TIMPs (TIMP-1, -2, -3 and -4). TIMP2 acts as inhibitor or activator of MMPs. TIMP-2 is required with MMP14 for the activation of pro-MMP2. The present study has not addressed the role of the complex interactional network of MMPs/TIMPS in hypertension and vascular injury, for which additional studies will be required.
Conclusions and perspectives
This study demonstrated using Mmp2 null mice that MMP2 mediates effects of Ang II leading to endothelial dysfunction, vascular remodelling, oxidative stress, and inflammation. These effects are mediated at least in part through the role that MMP2 plays via shedding of HB-EGF that stimulate EGFR/ERK1/2 signalling in VSMCs, or through enhanced Mmp2 expression in infiltrating immune cells. BM transplantation experimental results revealed a role for immune cell MMP2 in Ang II-induced BP elevation and for both vascular and immune cell MMP2 in Ang II-induced endothelial dysfunction. Understanding the mechanism of action of MMP2 in immune and vascular cells may reveal new therapeutic targets for the treatment of hypertension and vascular disease.
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